Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



The Greatest Thing Since Sliced Bread Has Arrived for MS Patients

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Last November, I examined five experimental drugs that appeared as if they had all of the tools necessary to become life-changing blockbusters from a financial and quality of life perspective. Yesterday, the first experimental drug I highlighted from Biogen Idec (NASDAQ: BIIB  ) was approved by the Food and Drug Administration as a first-line treatment for relapsing MS.

Pardon the cliche, but I believe the greatest thing since sliced bread has just been bestowed upon MS patients whether they realize it yet or not.

Greater efficacy with fewer side effects is possible!
Tecfidera -- previously known as BG-12 in trials -- was studied in two different clinical trials known as Confirm and Define. In its Confirm study, Biogen noted that its pill, administered twice daily, reduced the rate of MS relapses by an impressive 49%, and was associated with a 71% to 99% drop in new or expanding lesions in both trials.

What's truly unique about Tecfidera is its adverse events profile, which demonstrates the promise of fewer side effects with better efficacy. The most common side effects exhibited by patients on Tecfidera were flushing and gastrointestinal events, which often resulted in very low trial dropout rates. Biogen's new medication could also lower lymphocyte counts in patients, according to its press release. 

However, compare this to Novartis' (NYSE: NVS  ) Gilenya or Sanofi's (NYSE: SNY  ) Aubagio and you'll get a much clearer picture why Biogen's oral medication appears superior.

Gilenya, which is approved as both a first-line and second-line MS treatment within the U.S. and comes in pill form as well, has the potential to cause serious cardiovascular problems through slowing a patients' heart rate, can lower lymphocyte counts (similar to Tecfidera), and can potentially lead to macular edema or liver problems. Sure, it's a once-daily pill compared to Tecfidera, which is required to be taken twice a day, but the side effects are night-and-day visible to me.

Aubagio, another pill-based drug from Sanofi, comes with even harsher warnings in the form of an FDA black box warning label. The warning specifically notes that Aubagio can cause severe liver problems that can lead to death. Additional side effects for the second-line treatment include kidney problems, high blood pressure, and breathing problems.

When given the choice of these three drugs, even with Tecfidera's $50,000-$55,000 annual price tag, according to RBC Capital Markets analyst Michael Yee, I can almost assure you physicians and patients with any complication potential are going to opt for Biogen's therapy.  

Biogen's MS-sector domination
But, Biogen isn't done there. The growing biotech behemoth recently paid $3.25 billion to acquire a full working interest in IV-based MS therapy Tysabri from Elan (UNKNOWN: ELN.DL2  ) . The cash gives Elan the working capital to start over from a relatively empty portfolio while giving Biogen the chance to challenge Novarits, Sanofi, and Teva Pharmaceuticals (NYSE: TEVA  ) in the MS arena.

Trust me, there's little love lost in the MS sector with Teva's $4 billion MS drug, Copaxone, set to come off patent in two years. In fact, Teva had tried, unsuccessfully, to delay the FDA approval of Tecfidera on the grounds that there were signs of renal toxicity in its animal studies. As you can guess by yesterday's approval, Teva didn't win that argument and could now stand to lose Copaxone sales long before generics hit the market in 2015.

Now, it's up to Biogen to successfully price and launch Tecfidera, as well as get this revolutionary capsule approved in the EU where the Committee for Medicinal Products for Human Use (CHMP) recommended approval of the drug last week. Assuming Biogen doesn't pull a Dendreon and completely blow the launch, and Tecfidera gains approval from the European Medicines Agency in the second-quarter, we could be looking at better than $4 billion in worldwide sales by 2017.

That is one mighty fine slice of bread if I don't say so myself!

While you can certainly make huge gains in biotechs like Biogen, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Read/Post Comments (4) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 02, 2013, at 3:43 PM, lindschicago wrote:

    As someone with MS, I found this article very insensitive. The best thing since sliced bread? Hmmm, that might be a cure. And whether or not we realize it?

    Here's a drug, it will probably cost you $3K a month, it might REDUCE the number of relapses you have by 50%, but won't actually prevent MS progression (there is a difference). And the only side effect we know about so far is: reduced blood cell count, and major GI issues.

    I really hope this drug helps people, but it's nothing I am ecstatic over.

  • Report this Comment On April 08, 2013, at 2:23 PM, Griffith26 wrote:

    I agree that this article is insensitive. This new medication is not a cure, and in fact doesn't show to be more effective than therapies currently available. We should have learned by now not to make safety assumptions about MS products before they've been on the market for a while. Much of what is known about safety issues with other medications was NOT known at drug approval. And do you really anticipate quality of life improvements from a pill that had more discontinuation than a daily injection?

  • Report this Comment On April 22, 2013, at 2:52 AM, lindschicago wrote:

    Also, the author might want to look into this company. The submitted another drug they produced for FDA approval after completing only 1/4 of the standard required research for most drugs. And a bunch of people wound up with a rare brain infection that usually causes

    death or severe disability. This infection is called progressive multifocal

    leukoencephalopathy (PML). The same brain infection you might get if you have AIDS.

  • Report this Comment On January 13, 2014, at 11:24 AM, bugmenot wrote:

    It seems insensitve because it is. He probably knows nothing about MS or the drug. He is writer for profit...thats it. Articles for ad revenue.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2336454, ~/Articles/ArticleHandler.aspx, 9/28/2016 4:38:28 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 7 hours ago Sponsored by:
DOW 18,228.30 133.47 0.74%
S&P 500 2,159.93 13.83 0.64%
NASD 5,305.71 48.22 0.92%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/27/2016 4:00 PM
BIIB $314.53 Up +4.71 +1.52%
Biogen CAPS Rating: *****
ELN.DL2 $0.00 Down +0.00 +0.00%
Elan CAPS Rating: ***
NVS $80.88 Up +0.15 +0.19%
Novartis CAPS Rating: ****
SNY $38.15 Up +0.11 +0.29%
Sanofi CAPS Rating: *****
TEVA $49.47 Down -0.80 -1.59%
Teva Pharmaceutica… CAPS Rating: ****